Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial.

File TM, Goldberg L, Das A, Sweeney C, Saviski J, Gelone SP, Seltzer E, Paukner S, Wicha WW, Talbot GH, Gasink LB.

Clin Infect Dis. 2019 Oct 18. pii: ciz710. doi: 10.1093/cid/ciz710. [Epub ahead of print] No abstract available.

PMID:
31626688
2.

Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial.

Alexander E, Goldberg L, Das AF, Moran GJ, Sandrock C, Gasink LB, Spera P, Sweeney C, Paukner S, Wicha WW, Gelone SP, Schranz J.

JAMA. 2019 Sep 27. doi: 10.1001/jama.2019.15468. [Epub ahead of print]

PMID:
31560372
3.

Prediction of lefamulin epithelial lining fluid penetration after intravenous and oral administration using Phase 1 data and population pharmacokinetics methods.

Zhang L, Wicha WW, Bhavnani SM, Rubino CM.

J Antimicrob Chemother. 2019 Apr 1;74(Supplement_3):iii27-iii34. doi: 10.1093/jac/dkz088.

4.

Pharmacokinetics/pharmacodynamics of lefamulin in a neutropenic murine pneumonia model with Staphylococcus aureus and Streptococcus pneumoniae.

Wicha WW, Strickmann DB, Paukner S.

J Antimicrob Chemother. 2019 Apr 1;74(Supplement_3):iii11-iii18. doi: 10.1093/jac/dkz086.

5.

In vivo pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model.

Wicha WW, Craig WA, Andes D.

J Antimicrob Chemother. 2019 Apr 1;74(Supplement_3):iii5-iii10. doi: 10.1093/jac/dkz085.

6.

Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia.

Bhavnani SM, Zhang L, Hammel JP, Rubino CM, Bader JC, Sader HS, Gelone SP, Wicha WW, Ambrose PG.

J Antimicrob Chemother. 2019 Apr 1;74(Supplement_3):iii35-iii41. doi: 10.1093/jac/dkz089.

7.

Pharmacokinetics and tolerability of lefamulin following intravenous and oral dosing.

Wicha WW, Prince WT, Lell C, Heilmayer W, Gelone SP.

J Antimicrob Chemother. 2019 Apr 1;74(Supplement_3):iii19-iii26. doi: 10.1093/jac/dkz087.

8.

Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial.

File TM, Goldberg L, Das A, Sweeney C, Saviski J, Gelone SP, Seltzer E, Paukner S, Wicha WW, Talbot GH, Gasink LB.

Clin Infect Dis. 2019 Nov 13;69(11):1856-1867. doi: 10.1093/cid/ciz090.

9.

Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid.

Zeitlinger M, Schwameis R, Burian A, Burian B, Matzneller P, Müller M, Wicha WW, Strickmann DB, Prince W.

J Antimicrob Chemother. 2016 Apr;71(4):1022-6. doi: 10.1093/jac/dkv442. Epub 2016 Jan 7.

PMID:
26747098
10.

Population pharmacokinetic analyses for BC-3781 using phase 2 data from patients with acute bacterial skin and skin structure infections.

Rubino CM, Xue B, Bhavnani SM, Prince WT, Ivezic-Schoenfeld Z, Wicha WW, Ambrose PG.

Antimicrob Agents Chemother. 2015 Jan;59(1):282-8. doi: 10.1128/AAC.02033-13. Epub 2014 Oct 27.

Supplemental Content

Loading ...
Support Center